Company Shares of Neovasc Rally 89.8%

Neovasc (NASDAQ:NVCN) has climbed 89.8% in the past week and advanced 66.28% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 92.08% and the outperformance has advanced to 64.77% for the last 4 weeks period.

Neovasc (NASDAQ:NVCN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.54 and $0.52 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.88. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.76, notching a gain of 49.39% for the day. The total traded volume was 18,348,645 . The stock had closed at $0.51 on the previous day.

The company shares have dropped -89.46% from its 1 Year high price. On Jun 23, 2015, the shares registered one year high at $7.49 and the one year low was seen on May 20, 2016. The 50-Day Moving Average price is $1.35 and the 200 Day Moving Average price is recorded at $3.20.

Many analysts have stated their opinion on the company shares. In the latest statement by the brokerage house, Ladenburg Thalmann downgrades its outlook on Neovasc (NASDAQ:NVCN). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Buy. The rating by the firm was issued on May 20, 2016. Institutional Investors own 44.23% of Neovasc shares.

Neovasc Inc. is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Reducer for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Its Tiara is a product for treating mitral valve disease. The Tiara is in preclinical/early clinical stage development to provide an invasive transcatheter device. The Tiara valve is made up of two components: the leaflets and skirt. It produces Peripatch, a biological tissue product that is manufactured from pericardium, which is the protective sac that surrounds the heart of an animal. It provides product development and specialized manufacturing services related to Peripatch tissue-based products.

Leave a Reply

Brian Harris - Is it time to Sell?

Top Brokerage Firms are advising their investors on Brian Harris. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.